Learn more about Emgality when you register with us. Please enter your information below.
You are now registering to receive information about Emgality intended only for healthcare providers. By submitting the information requested below, you certify that you are a healthcare provider. Lilly's intent is to only provide information to healthcare providers.
Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.
Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.
The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.
Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the device.
GZ HCP ISI 14SEP2022
Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated in adults for the: